Results 31 to 40 of about 9,786 (244)

A speciation study on the perturbing effects of iron chelators on the homeostasis of essential metal ions [PDF]

, 2015
A number of reports have appeared in literature calling attention to the depletion of essential metal ions during chelation therapy on beta-thalassaemia patients. We present a speciation study to determine how the iron chelators used in therapy interfere
Alberti G, Biesuz R., Crespo Alonso M, CRISPONI, GUIDO, NURCHI, VALERIA MARINA, Sanna G, Zoroddu MA   +6 more
core   +6 more sources

Synthesis and Characterization of Deferasirox PLGA Nanoparticles and Investigation of Toxicity in Cell Model

Journal of Mazandaran University of Medical Sciences, 2022
Background and purpose: Cancer is one of the causes of mortality worldwide. Evidence suggests that iron depletion by a chelator agent suppresses the development of some cancer cells. Deferasirox is shown to have anticancer properties.
Hamidreza Mohammadi, Javad Akhtari, Sara Assadpour, Mitra Kamali, Pedram Ebrahimnejad   +4 more
doaj  

Genetic polymorphisms influencing deferasirox pharmacokinetics, efficacy, and adverse drug reactions: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Objective: Deferasirox is an iron-chelating agent prescribed to patients with iron overload. Due to the interindividual variability of deferasirox responses reported in various populations, this study aims to determine the genetic polymorphisms that ...
Kittika Yampayon, Puree Anantachoti, Bunchai Chongmelaxme, Varalee Yodsurang, Varalee Yodsurang   +4 more
doaj   +1 more source

How early can myocardial iron overload occur in Beta thalassemia major? [PDF]

, 2014
BACKGROUND: Myocardial siderosis is the most common cause of death in patients with beta thalassemia major(TM). This study aimed at investigating the occurrence, prevalence and severity of cardiac iron overload in a young Chinese population with beta TM.
A Aessopos, AM Maceira, AW Leung, B Modell, B Modell, B Modell, BA Davis, C Borgna-Pignatti, DH Fitchett, DJ Weatherall, DT Kremastinos, F Alpendurada, G Barosi, Gaohui Yang, GM Brittenham, GM Brittenham, HF Pan, Hongfei Pan, JC Wood, JC Wood, JC Wood, JL Fernandes, K Tziomalos, Liling Long, Lisa Anderson, LJ Anderson, LJ Anderson, M Angastiniotis, M Bejaoui, M Westwood, MA Aldouri, MA Tanner, MA Tanner, MA Tanner, MAEM Engle, NF Olivieri, P Kirk, Peng Peng, Q Meng, Rongrong Liu, Shaohong Tan, T He, Taigang He, V Positano, Weijia Yang, Xiaolei Xu, Xingjiang Long, Xinhua Zhang, Yong-rong Lai, Yongrong Lai   +49 more
core   +2 more sources

Deferasirox (Exjade®) for the Treatment of Iron Overload [PDF]

Acta Haematologica, 2009
Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia ...
M.D. Cappellini, A. Taher
openaire   +2 more sources

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

Haematologica, 2011
Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and ...
Alessia Pepe, Antonella Meloni, Marcello Capra, Paolo Cianciulli, Luciano Prossomariti, Cristina Malaventura, Maria Caterina Putti, Alma Lippi, Maria Antonietta Romeo, Maria Grazia Bisconte, Aldo Filosa, Vincenzo Caruso, Antonella Quarta, Lorella Pitrolo, Massimiliano Missere, Massimo Midiri, Giuseppe Rossi, Vincenzo Positano, Massimo Lombardi, Aurelio Maggio   +19 more
doaj   +1 more source

Coordination chemistry and biology of chelators for the treatment of iron overload disorders [PDF]

, 2007
Treatment of the medical condition generally referred to as iron overload through the delivery of chelators has recently received a major boost. In 2005 Novartis gained FDA approval for the drug deferasirox, which may be taken orally.
al-Refaie, al-Refaie, Allen, Anderegg, Armstrong, Atanasiu, Baker, Becker, Berdoukas, Bergeron, Bernhardt, Bernhardt, Bernhardt, Bernhardt, Brunner, Burkitt, Charalambous, Clarke, Dhungana, Dhungana, Dobbin, Donovan, Dragsten, Dunford, Fabio, Faller, Farrugia, Fischer, Ganguly, Ganz, Ghugre, Gyparaki, Ha, Hahn, Harris, Heinz, Henle, Hershko, Hershko, Hider, Hossain, Hossain, Kalinowski, Keberle, Kline, Kontoghiorghes, Kontoghiorghes, Kontoghiorghes, Kontoghiorghes, Kontoghiorghes, Kontoghiorghes, Kontoghiorghes, Langemann, Lu, Maichle, Mathur, Merkofer, Naegeli, Nathan, Neufeld, Olivieri, Olivieri, Olivieri, Origa, Pang, Paul V. Bernhardt, Polomoscanik, Porter, Porter, Prelog, Raymond, Rice-Evans, Spasojevic, Steinhauser, Stumpf, Tam, Tam, Tripod, Van der Helm, Vichinsky, Wong, Wood   +81 more
core   +1 more source

The potential of deferasirox as a novel therapeutic modality in gastric cancer [PDF]

, 2016
Background: Iron is a crucial element for cell proliferation, growth, and metabolism. However, excess iron and altered iron metabolism are both associated with tumor initiation and tumor growth. Deferasirox is an oral iron chelator. Although some studies
���������
core   +1 more source

Acute kidney injury due to thin basement membrane disease mimicking Deferasirox nephrotoxicity: a case report

BMC Nephrology, 2018
Background Although the renal toxicity of Deferasirox, an oral iron chelator, has been reported to be mild, there have been reports of acute interstitial nephritis or Fanconi syndrome due to this agent.
Keiko Oda, Kan Katayama, Akiko Tanoue, Tomohiro Murata, Yumi Hirota, Shoko Mizoguchi, Yosuke Hirabayashi, Takayasu Ito, Eiji Ishikawa, Kaoru Dohi, Masaaki Ito   +10 more
doaj   +1 more source

Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major [PDF]

, 2017
Chronic hepatitis C (CHC) significantly affects the prognosis of liver disease [1] and health related quality of life (HRQOL) in patients with β-thalassemia major [2, 3].
Biliotti, Elisa, Esvan, Rozenn, Franchi, Cristiana, Palazzo, Donatella, Serani, Marco, Silvestri, Alessandro M., Sorrentino, Francesco, Spaziante, Martina, Taliani, Gloria, Volpicelli, Lorenzo   +9 more
core   +1 more source